Egetis Therapeutics AB (publ) (EGTX) - Total Liabilities
Based on the latest financial reports, Egetis Therapeutics AB (publ) (EGTX) has total liabilities worth Skr288.70 Million SEK (≈ $31.07 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Egetis Therapeutics AB (publ) current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Egetis Therapeutics AB (publ) - Total Liabilities Trend (2008–2025)
This chart illustrates how Egetis Therapeutics AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see EGTX total asset value.
Egetis Therapeutics AB (publ) Competitors by Total Liabilities
The table below lists competitors of Egetis Therapeutics AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ARTS Group Co Ltd
SHG:603017
|
China | CN¥1.89 Billion |
|
Shenzhen Mingdiao Decoration Co Ltd
SHE:002830
|
China | CN¥663.45 Million |
|
Shanghai Lianming Machinery Co Ltd
SHG:603006
|
China | CN¥482.82 Million |
|
Zinwell Corporation
TW:2485
|
Taiwan | NT$893.47 Million |
|
Mangalore Chemicals & Fertilizers Limited
NSE:MANGCHEFER
|
India | Rs-10.65 Billion |
|
Jiangyin Pivot Automotive Products Co. Ltd.
SHE:301181
|
China | CN¥215.50 Million |
|
Brasilagro Adr
NYSE:LND
|
USA | $1.78 Billion |
|
Lanner Electronics
TWO:6245
|
Taiwan | NT$2.89 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Egetis Therapeutics AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Egetis Therapeutics AB (publ) (EGTX) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Egetis Therapeutics AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Egetis Therapeutics AB (publ) (2008–2025)
The table below shows the annual total liabilities of Egetis Therapeutics AB (publ) from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr300.40 Million ≈ $32.33 Million |
+0.33% |
| 2024-12-31 | Skr299.40 Million ≈ $32.22 Million |
+39.52% |
| 2023-12-31 | Skr214.60 Million ≈ $23.09 Million |
+290.89% |
| 2022-12-31 | Skr54.90 Million ≈ $5.91 Million |
+30.00% |
| 2021-12-31 | Skr42.23 Million ≈ $4.54 Million |
-84.02% |
| 2020-12-31 | Skr264.34 Million ≈ $28.45 Million |
+949.09% |
| 2019-12-31 | Skr25.20 Million ≈ $2.71 Million |
+11.12% |
| 2018-12-31 | Skr22.68 Million ≈ $2.44 Million |
+94.52% |
| 2017-12-31 | Skr11.66 Million ≈ $1.25 Million |
+69.61% |
| 2016-12-31 | Skr6.87 Million ≈ $739.64K |
+58.77% |
| 2015-12-31 | Skr4.33 Million ≈ $465.87K |
-66.21% |
| 2014-12-31 | Skr12.81 Million ≈ $1.38 Million |
+215.75% |
| 2013-12-31 | Skr4.06 Million ≈ $436.60K |
-37.74% |
| 2012-12-31 | Skr6.52 Million ≈ $701.23K |
+67.36% |
| 2011-12-31 | Skr3.89 Million ≈ $418.98K |
+159.12% |
| 2010-12-31 | Skr1.50 Million ≈ $161.69K |
+448.39% |
| 2009-12-31 | Skr273.98K ≈ $29.48K |
-15.32% |
| 2008-12-31 | Skr323.55K ≈ $34.82K |
-- |
About Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for… Read more